Eli Lilly (LLY) announced the upcoming retirement of Anne White, a pivotal figure in its neuroscience division, and entered a ...

Anne White, a 30-year company veteran who previously led the company’s oncology unit, will step down as head of Lilly ...

Eli Lilly (LLY) stock in focus as the company's neuroscience chief Anne White retires, and the firm begins an executive ...

Eli Lilly's top neuroscience executive, Anne White, is retiring after three decades with the drugmaker. Eli Lilly on Wednesday said White will remain in her post as executive vice president and ...

Eli Lilly and Company (NYSE: LLY) today announced that Anne White, executive vice president and president, Lilly Neuroscience ...

Treatment with adagrasib (Krazati) significantly improved progression-free-survival (PFS) in previously treated patients with ...

Earnings season marches on, with Eli Lilly among the big names yet to report this week. President Trump has said he will name replacements this week for Federal Reserve governor Adriana Kugler and ...

Eli Lilly shares tumble over 10% after disappointing weight-loss pill data Lilly’s results from an obesity pill study didn’t perform as well as Wall Street expected.

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight loss options after a 72-week period.

The Dow and S&P 500 eased on Thursday, as shares of Eli Lilly dropped after data from its oral weight loss drug disappointed, while the Nasdaq eked out a record closing high.